SR-9011: The Next-Generation Rev-Erbα Research Compound
Last updated: March 2026
🔬 HighPeptides Editorial Note — SR9011 is reviewed alongside HighPeptides' MK-677, Cardarine, and SARM pages — research chemical, not a peptide.
SR-9011 is a second-generation Rev-Erbα agonist developed to improve upon SR-9009 (Stenabolic). It targets the same circadian nuclear receptor pathway with claims of improved CNS penetration and receptor potency. It is among the least-studied compounds in the research chemical space — animal data only, extremely limited.
🧪 Buy Sr9011 Guide at Swiss Chems →Nuclear receptor NR1D1
Improved over SR-9009
Animal studies only
How SR-9011 Works
SR-9011 shares the same core mechanism as SR-9009 — Rev-Erbα agonism — but with structural modifications intended to improve pharmacokinetics. It activates the same nuclear receptor that controls circadian clock gene expression and downstream metabolic pathways.
SR-9011 binds and activates Rev-Erbα (NR1D1), the circadian nuclear receptor. This represses BMAL1 clock gene expression, altering the expression of hundreds of metabolic target genes. The downstream effects mirror SR-9009: fat oxidation upregulation, mitochondrial biogenesis, reduced lipogenesis.
Research from Scripps suggests SR-9011 has better CNS (blood-brain barrier) penetration than SR-9009. This makes it potentially useful for studying Rev-Erbα's role in mood, anxiety, and addiction circuits. Some preclinical work has explored its effects on cocaine-seeking behavior in rodents.
Like SR-9009, SR-9011 modulates genes involved in fat synthesis, fat oxidation, glucose uptake, and inflammation. FASN (fatty acid synthase) is downregulated; CPT1 (carnitine palmitoyltransferase) is upregulated. These shifts theoretically increase fat burning — again, demonstrated in animal models only.
While SR-9011 was designed to improve pharmacokinetics, the oral bioavailability problem of this compound class has not been fully resolved in published literature. Most SR-9011 research still uses injection administration. Assuming oral SR-9011 is bioavailable based on vendor claims is not supported by peer-reviewed data.
What Preclinical Studies Show
⚠️ All data below is from animal studies (primarily mouse/rodent models). SR-9011 is one of the least-studied compounds in this space. Extreme caution warranted.
Side Effects & Risks
Key Takeaways
- SR-9011 is a Rev-Erbα agonist — NOT a SARM
- Shows improved CNS penetration vs SR-9009 in animal models
- Higher in vitro binding affinity for Rev-Erbα receptor
- Does not bind the androgen receptor — no HPTA suppression
- Some preclinical anxiety and mood effects observed in rodents
- Zero approved human clinical trials exist
- Oral bioavailability in humans is uncharacterized
- Long-term safety profile is completely unknown
- Whether improved CNS penetration is a benefit or additional risk
🛒 Recommended Products
Research monitoring supplies for metabolic and circadian compounds.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides uses them as a primary vendor reference.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational purposes only. It is not medical advice. SR-9011 is not FDA approved and is not intended for human use. It is one of the least-studied compounds available in research chemical markets. All efficacy data comes from preclinical animal studies. Do not use any research chemical without consulting a qualified medical professional.